PROSPECTIVE, RANDOMIZED TRIAL OF TICAGRELOR VERSUS PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME

Phase 4

Recruiting

• Conditions: I20.0; I21; I24.9; Unstable angina; Acute myocardial infarction; Acute ischaemic heart disease, unspecified

• Registration Number: DRKS00005441
• Lead Sponsor: Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-11-18
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 4000

Inclusion Criteria

Patients presenting with ACS and planned invasive strategy; Informed, written consent

Exclusion Criteria

Active bleeding; History of stroke or TIA;
Need for oral anticoagulation;
Chronic renal insufficiency requiring dialysis;
Moderate or severe hepatic dysfunction

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Composite of death, myocardial infarction or stroke at 12 months after randomization

Secondary Outcome Measures

Name	Time	Method
Safety endpoint: Bleeding according to BARC criteria (BARC class 3-5) at 12 months after randomization; the individual components of the primary endpoint at 12 months after randomization;<br>Stent thrombosis according to ARC criteria (definite and probable) at 12 months after randomization<br>